NEXI NexImmune Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NEXI

Price (delayed)

$3.12

Market cap

$4.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$30.82

Enterprise value

$1.12M

NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T ...

Highlights
NEXI's debt has dropped by 93% year-on-year and by 89% since the previous quarter
The EPS has surged by 53% year-on-year and by 27% since the previous quarter
NEXI's equity has dropped by 89% year-on-year and by 57% since the previous quarter
NexImmune's quick ratio has shrunk by 81% YoY and by 57% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.neximmune.com
Peers: OMER OMGA

Key stats

What are the main financial stats of NEXI
Market
Shares outstanding
1.37M
Market cap
$4.28M
Enterprise value
$1.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$32.34M
EBITDA
-$30.78M
Free cash flow
-$31.47M
Per share
EPS
-$30.82
Free cash flow per share
-$29.99
Book value per share
$3.32
Revenue per share
$0
TBVPS
$8.19
Balance sheet
Total assets
$8.59M
Total liabilities
$5.08M
Debt
$68,809
Equity
$3.51M
Working capital
$316,727
Liquidity
Debt to equity
0.02
Current ratio
1.06
Quick ratio
0.63
Net debt/EBITDA
0.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-167.4%
Return on equity
-247.2%
Return on invested capital
-3,024.2%
Return on capital employed
-921.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEXI stock price

How has the NexImmune stock price performed over time
Intraday
-5.17%
1 week
-8.5%
1 month
-41.79%
1 year
-60.71%
YTD
40.54%
QTD
-44.39%

Financial performance

How have NexImmune's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$32.97M
Net income
-$32.34M
Gross margin
N/A
Net margin
N/A
NexImmune's net income has increased by 48% YoY and by 26% from the previous quarter
NexImmune's operating income has increased by 48% YoY and by 26% from the previous quarter

Growth

What is NexImmune's growth rate over time

Valuation

What is NexImmune stock price valuation
P/E
N/A
P/B
0.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 53% year-on-year and by 27% since the previous quarter
NEXI's equity has dropped by 89% year-on-year and by 57% since the previous quarter
The stock's P/B is 88% more than its last 4 quarters average of 0.5

Efficiency

How efficient is NexImmune business performance
The return on equity has dropped by 104% year-on-year and by 14% since the previous quarter
The ROA has dropped by 64% year-on-year and by 7% since the previous quarter
The ROIC has grown by 49% from the previous quarter

Dividends

What is NEXI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEXI.

Financial health

How did NexImmune financials performed over time
The total assets is 69% more than the total liabilities
NexImmune's quick ratio has shrunk by 81% YoY and by 57% QoQ
The total assets has plunged by 80% YoY and by 41% from the previous quarter
NEXI's debt is 98% smaller than its equity
NEXI's debt has dropped by 93% year-on-year and by 89% since the previous quarter
NEXI's equity has dropped by 89% year-on-year and by 57% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.